TY - JOUR
T1 - Fractionated administration of irinotecan and cisplatin for treatment of non-small-cell lung cancer
T2 - A phase II study of Okayama Lung Cancer Study Group
AU - Ueoka, H.
AU - Tanimoto, Mitsune
AU - Kiura, K.
AU - Tabata, M.
AU - Takigawa, N.
AU - Segawa, Y.
AU - Takata, I.
AU - Eguchi, K.
AU - Okimoto, N.
AU - Harita, S.
AU - Kamei, H.
AU - Shibayama, T.
AU - Watanabe, Y.
AU - Hiraki, S.
AU - Harada, M.
PY - 2001/7/6
Y1 - 2001/7/6
N2 - A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg m -2 was given first and followed by CPT-11 at a dose of 50 mg m -2. Both drugs were given by 1 -hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles, 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32-63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities.
AB - A phase II study of fractionated administration of irinotecan (CPT-11) and cisplatin (CDDP) in patients with non-small-cell lung cancer (NSCLC) was conducted. Between January 1996 and January 1998, 44 previously untreated patients with stage IIIB or IV NSCLC were enrolled. CDDP at a dose of 60 mg m -2 was given first and followed by CPT-11 at a dose of 50 mg m -2. Both drugs were given by 1 -hour infusion on days 1 and 8, and repeated every 4 weeks up to 4 cycles, 42 patients were evaluated for response and 44 for survival and toxicity. 20 patients (48%: 95% confidence interval 32-63%) achieved an objective response. The median duration of responses was 8 months, and the median survival time and the 1-year survival rate were 12.5 months and 56.8%, respectively. Major toxicities were neutropenia and diarrhoea. Grade 3 or 4 neutropenia occurred in 70.5% of the patients and one patient died of sepsis. Grade 3 or 4 diarrhoea was experienced in 25.0%, but manageable by conventional therapy. In conclusion, fractionated administration of CPT-11 and CDDP was highly effective for advanced NSCLC with manageable toxicities.
KW - Cisplatin
KW - Fractionated administration
KW - Irinotecan
KW - Non-small-cell lung cancer
KW - Phase II study
UR - http://www.scopus.com/inward/record.url?scp=17844372728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=17844372728&partnerID=8YFLogxK
U2 - 10.1054/bjoc.2001.1861
DO - 10.1054/bjoc.2001.1861
M3 - Article
C2 - 11437395
AN - SCOPUS:17844372728
VL - 85
SP - 9
EP - 13
JO - British Journal of Cancer
JF - British Journal of Cancer
SN - 0007-0920
IS - 1
ER -